Compare Ascendis Pharma A/S (ASND) vs AngloGold Ashanti Limited (AU) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs AngloGold Ashanti Limited — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while AngloGold Ashanti Limited trades at $80.28 (market cap $41.51B). The key difference: AngloGold Ashanti Limited is far larger — about 2.3× Ascendis Pharma A/S's market cap, and AngloGold Ashanti Limited pays a 5.6% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | AU | |
|---|---|---|
Market Cap | $17.74B | $41.51B |
Sector | Health | Basic Materials |
52-Week High | $277.18 | $128.26 |
52-Week Low | $163.32 | $46.25 |
Enterprise Value | $18.11B | $40.64B |
Dividend Yield | — | 5.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
AngloGold Ashanti (AU) trades at $82.10, up 0.23% on the day, with a bearish technical signal but strong fundamentals. Recent Q1 2026 earnings beat expectations with EPS of $2.52 versus $2.27 forecast. The company shows robust revenue growth, with 2025 revenue at $9.89 billion and net income margin of 26.64%. A proposed share repurchase program and a $1.16 dividend for H1 2026 highlight capital returns. Analyst consensus is bullish with a $116.25 price target, though technical indicators suggest near-term resistance.
Outlook remains positive driven by gold price strength and operational efficiency, but risks include geopolitical exposure and commodity volatility. The stock offers value with a P/E of 12.06 and high ROE of 45.39%, yet bearish technical trends and recent earnings misses in Q3 and Q4 2025 warrant caution. Institutional sentiment is mixed, with 64% buy ratings but technical selling pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About AngloGold Ashanti Limited
Anglogold Ashanti Ltd is one of the largest gold miners. The company also produces silver and sulphuric acid as by-products. Its operating divisions are Africa, Australia, and the Americas. The firm generates a majority of its revenue from Africa which includes Ghana, Guinea, Mali, the Democratic Republic of the Congo, and Tanzania.
Read more on AU →
